



Not for Retail distribution: this document is intended exclusively for Professional, Institutional, Qualified or Wholesale Investors / Clients, as defined by applicable local laws and regulation. Circulation must be restricted accordingly

# ACT MA People & Planet

## Markets Stabilise After a Robust Ten-Month Rally

- Changes in FED policy and concerns over AI valuation influence market movements
- Optimism for peace in Ukraine increased as the US endorsed a peace framework
- Marginal gains in defensive sectors fail to offset broader challenges this month

**Laurent Ramsamy**  
**Lead Portfolio Manager**

### What's happening?

Looking for Normalisation, there are emerging signs that the White House is moving away from policy radicalism. Recent concessions to China aimed at maintaining the trade truce, along with new tariff exemptions on basic goods such as coffee, indicate that the U.S. administration acknowledges the negative impact of the trade war on consumer purchasing power—though this shift remains tentative.

In the U.S., job creation rebounded above expectations in September, but downward revisions to previous months reveal a slowdown following April's tariff announcements. The unemployment rate climbed to 4.4%, its highest level since October 2021, while dovish comments from the Federal Reserve offered some market relief, leaving a December rate cut uncertain.

In the Eurozone, GDP growth accelerated to 0.2% quarter-on-quarter in Q3, with underlying data painting a more optimistic picture. Persistent services inflation and reduced downside risks have closed the door on near-term ECB cuts, though we still anticipate one final reduction in March 2026 as headline inflation bottoms out and downside risks re-emerge.

Meanwhile, China's growth momentum weakened in October, with fixed asset investment posting its sharpest decline since the pandemic—down 11.4% year-on-year—amid continued weakness in manufacturing and infrastructure. Although fiscal support announced in late October has yet to materialize in the data, we expect improvement in the coming months.

Looking ahead, central banks are likely to adjust policy gradually: the Fed is expected to deliver a series of insurance cuts, lowering rates to 3.0% by Q3 2026; the ECB may cut once more to 1.75% in March 2026; the Bank of England's rate could fall to 3.5% by year-end 2026; and the Bank of Japan is projected to hike to 0.75% in January, supported by a positive domestic outlook.

## Portfolio positioning and performance

ACT MA PEOPLE & PLANET			
	Dec-24	Oct-25	Nov-25
<b>Net Equity</b>	<b>69,3%</b>	<b>70,4%</b>	<b>71,8%</b>
Equities	69,3%	70,4%	71,8%
Equities derivatives	0,0%	0,0%	0,0%
Risk Mitigation Strategies	0,0%	0,0%	0,0%
<b>Fixed Income</b>	<b>26,5%</b>	<b>28,4%</b>	<b>28,1%</b>
Govies	6,9%	8,0%	8,0%
Bond Derivatives	16,8%	4,5%	0,5%
High Yield Credit	1,5%	1,0%	1,0%
Investment Grade	16,5%	18,1%	17,6%
Emerging Debt	1,5%	1,4%	1,5%
<b>Diversification</b>	<b>0,0%</b>	<b>0,0%</b>	<b>0,0%</b>
<b>Cash &amp; Money Market</b>	<b>4,1%</b>	<b>1,2%</b>	<b>0,1%</b>

November proved to be a challenging month for global markets, characterized by increased volatility and widespread declines across various asset classes. Equity markets faced downward pressure amid ongoing inflation concerns, expectations of tighter monetary policy, and geopolitical uncertainties. In response, the portfolio reduced cash holdings and tactically repositioned to capitalize on emerging opportunities and maintain flexibility in a turbulent environment. Most equity exposures posted declines, particularly in the real estate sector, which was impacted by rising interest rates and fears of economic slowdown. While some defensive sectors like healthcare and utilities performed relatively better, supported by stable demand fundamentals and their resilience in uncertain times. However, these gains were not enough to offset the broader challenges faced by the portfolio.

Fixed income allocations fared somewhat better but still experienced some softness. Despite signs of stabilization in market sentiment, bond prices remained volatile, driven by shifting expectations around monetary as the markets flipped sentiment around the Fed's December meeting. Overall, fixed income performance was modest; however, our focus on investment-grade assets helped cushion downside risks and protect capital. We continue to carefully manage duration risk and favour bonds with strong credit profiles, aiming to generate income while preserving capital in an environment that remains potentially volatile.

Given the complex macroeconomic landscape, our strategy remains cautious and vigilant. Ongoing geopolitical tensions and signs of slower economic growth impacted markets such as Japan, where tensions with China influenced investor sentiment. Similarly, Canadian markets were affected by shifts in the labour market and fluctuations in commodity prices. We remain attentive to these evolving risks, adjusting our positioning to navigate a landscape marked by uncertainty..

### Focus stock of the month:



: AstraZeneca is a British and Swedish multinational pharmaceutical and biotechnology company with headquarters at Cambridge's Biomedical Campus. Founded through the merger of Swedish Astra AB and the British Zeneca Group in 1999, it provides today a portfolio of products for major diseases in areas including oncology, cardiovascular and neuroscience. It also contributed in 2020 to the developments of the COVID-19 vaccine research and development. The

company primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index, but it is also listed on Nasdaq Stockholm and as a Nasdaq-100 company in the American markets.

AstraZeneca made notable contributions to sustainable development and innovation in recent months through:

7.2 and 7.3: AstraZeneca has committed to the Science Based Targets initiative (SBTi) and aims to reach net-zero emissions across its value chain by 2045. In 2024, AstraZeneca launched its “Ambition Zero Carbon” strategy, successfully sourcing 97% of electricity from certified renewable sources and reducing global Scope 1 and 2 emissions by 78% compared to 2015. Its operations in Sweden achieved a 98% reduction in emissions 18 months ahead of schedule, exemplifying its leadership in decarbonization.

9.5: AstraZeneca invested over 8% of its revenue into healthcare access initiatives in 2024, reinforcing its leadership in equitable healthcare delivery. The company supported programs that reached over 90 million people globally, including underserved communities in low- and middle-income countries. A key focus was expanding access to life-saving medicines through tiered pricing, patient assistance programs, and innovative delivery models. For instance, AstraZeneca's Healthy Heart Africa program has provided screening and treatment for over 12.9 million individuals with elevated blood pressure since 2014, significantly reducing healthcare disparities in Africa.

12.2: AstraZeneca operates ISO 14001-certified manufacturing facilities and actively promotes circular economy practices across its operations. In 2024, the company recycled over 85% of its process solvents, reprocessed chemical sludge, and recovered electronic-grade materials used in production, reducing waste sent to landfills to below 1% for the tenth consecutive year. Additionally, AstraZeneca has invested in sustainable water management practices, restoring over 3 million cubic meters of groundwater through efficient water reuse and conservation programs.

AstraZeneca's sustainability strategy especially focussed on the future of healthcare is deeply integrated in their business approach. By helping to build health systems resilience, improve health equity and decarbonize the operations, the company exemplifies how to operate as a sustainable global and science-led pharmaceutical company..

## Outlook:

Global investor attention has shifted from idiosyncratic issues in credit markets—despite persistent concerns around private credit highlighted in the financial press—to the outlook for Federal Reserve policy following the end of the U.S. government shutdown. The conclusion of 40 days of uncertainty is broadly positive for policy and market sentiment, albeit with one caveat: limited fresh labour market data ahead of the December Fed meeting. Several Board members have signalled the need for pragmatism and additional time before voting on another Fed Funds rate cut. Available data remains reassuring, showing a softening labour market trend without significant deterioration during the shutdown. If a December cut is delayed, January appears likely, as the Fed prioritizes credibility and stability in the U.S. dollar and Treasury markets. Importantly, investors should not interpret this as a reversal of the Fed's commitment to the three near-term insurance cuts outlined in September.

The backdrop remains supportive for risk assets. Earnings season delivered strong results across the U.S. and Europe, while policy accommodation from the Fed appears only delayed, not derailed. Limited macro data, complemented by alternative sources, shows no signs of slowing activity, with the Atlanta Fed's GDP Nowcast hovering near 4% annualized. In Europe, survey data has held firm despite lingering deflationary risks in core economies.

Investor positioning adds further support. Discretionary allocations remain below long-term equity norms, while systematic positioning—previously stretched—has begun to normalize, which should prove constructive over time. Near-term, cross-market volatility needs to subside, but structurally, our machine-learning Bull/Bear model continues to signal a bull market, intact since the U.S. policy pivot in late April.

Crypto market turbulence may have amplified recent risk aversion. Bitcoin's sharp correction (-33% from early October to late November) and weakness across other digital assets likely reduced retail buying power in equities. While institutional exposure remains minimal (0.4% of cash per BoA's November survey), U.S. retail investors are more heavily involved, and flow data confirms their seasonal absence. Encouragingly, retail-favoured momentum stocks appear to have bottomed at depressed levels, consistent with prior recovery patterns this year.

Credit markets remain resilient, reinforcing a neutral stance. Despite recent equity volatility and last month's focus on issuer-specific challenges, investment-grade CDS spreads have resisted widening. Issuance from AI corporates seeking infrastructure funding has surged, but cash-rich balance sheets suggest these firms are not driving stress or risk aversion. In summary, the combination of easier monetary policy, steady economic growth, enthusiasm for AI-driven infrastructure and productivity gains, ongoing fiscal stimulus in Germany, Japan, and China, and robust corporate earnings—even amid negative reactions to strong results from names like Nvidia—continues to underpin a constructive outlook for risk assets into 2026.

## Disclaimer

---

**Not for Retail distribution:** This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment. Due to this and the initial charge that is usually made, an investment is not usually suitable as a short term holding.

This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. The strategies discussed in this document may not be available in your jurisdiction.

Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

Please note that the management company reserves the right, at any time, to no longer market the product(s) mentioned in this communication in a European Union country by notification to its authority of supervision in accordance with European passport rules. In the event of dissatisfaction with the products or services, you have the right to make a complaint either with the marketer or directly with the management company (more information on our complaints policy available in English [here](#)). You also have the right to take legal or extra-judicial action at any time if you reside in one of the countries of the European Union. The European online dispute resolution platform allows you to enter a complaint form (by clicking [here](#)) and informs you, depending on your jurisdiction, about your means of redress (by clicking [here](#)).

Issued in the U.K. by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales, No: 01431068. Registered Office: 22 Bishopsgate, London, EC2N 4BQ. In other jurisdictions, this document is issued by AXA Investment Managers SA's affiliates in those countries.

In Hong Kong, this document is issued by AXA Investment Managers Asia Limited (SFC License No. AAP809), which is authorized and regulated by Securities and Futures Commission. This document is to be used only by persons defined as "professional investor" under Part 1 of Schedule 1 to the Securities and Futures Ordinance (SFO) and other regulations, rules, guidelines or circulars which reference "professional investor" as defined under Part 1 of Schedule 1 to the SFO. This document must not be relied upon by retail investors. Circulation must be restricted accordingly.

In Singapore, this document is issued by AXA Investment Managers Asia (Singapore) Ltd. (Registration No. 199001714W) and is intended for the use of Institutional Investors only as defined in Section 4A of the Securities and Futures Act (Cap. 289) and must not be relied upon by retail investors. Circulation must be restricted accordingly.

This document has been issued by AXA Investment Managers Asia (Singapore) Ltd (ARBN 115203622) ("AXA IM Asia"). AXA IM Asia is exempt from the requirement to hold an Australian Financial Services License and is regulated by the Monetary Authority of Singapore under Singaporean laws, which differ from Australian laws. AXA IM Asia offers financial services in Australia only to residents who are "wholesale clients" within the meaning of Corporations Act 2001 (Cth).

For Japanese clients: AXA Investment Managers Japan Ltd., whose registered office and principal place of business is at NBF Platinum Tower 14F 1-17-3 Shirokane, Minato-ku, Tokyo 108-0072, Japan, which is registered with the Financial Services Agency of Japan under the number KANTOZAIMUKYOKUCHO (KINSHO) 16, and is a member of Japan Securities Dealers Association, Type II Financial Instrument Firms Association, Investment Trust Association of Japan and Japan Investment Advisors Association to carry out the regulated activity of Financial Instrument Business under the Financial Instrument Exchange Law of Japan. In Japan, none of the funds mentioned in this document are registered under the Financial Instrument Exchange Law of Japan or Act on Investment Trusts and Investment Corporations. This document is purely for the information purpose for use by Qualified Institutional Investors defined by the Financial Instrument Exchange Law of Japan.

In Korea, AXA Investment Managers Asia (Singapore) Ltd is a registered Cross Border Investment Advisor/Discretionary Investment Management Company under the Financial Investment Services and Capital Markets Act (the "Act"). The activities referenced under the Act are 5-2-2 Investment Advisory Business and 6-2-2 Discretionary Investment Management Business, respectively. Its financial services are available in Korea only to Professional Investors within the meaning of Article 10 of Enforcement Decree of the Financial Investment Services and Capital Markets Act.

To the extent that any fund is mentioned in this document, neither the fund nor AXA IM Asia is making any representation with respect to the eligibility of any recipients of this document to acquire the units/shares in the fund under the laws of Korea, including but without limitation the Foreign Exchange Transaction Act and Regulations thereunder. The units/shares have not been registered under the Financial Investment Services and Capital Markets Act of Korea, and none of the units/shares may be offered, sold or delivered, or offered or sold to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to applicable laws and regulations of Korea.

In Taiwan, this document is issued by AXA Investment Managers Asia Limited (SFC License No. AAP809), which is authorized and regulated by Securities and Futures Commission. This document and the information contained herein are intended for the use of professional or institutional investors and should not be relied upon by retail investors. They have been prepared and issued for private informational and educational purposes only at the sole request of the specified recipients, and not intended for general circulation. They are strictly confidential, and must not be reproduced, circulated, distributed, redistributed or otherwise used, in whole or in part, in any way without the prior written consent of AXA IM Asia. They are not intended for distribution to any persons or in any jurisdictions for which it is prohibited.

If any fund is highlighted in this communication (the "Fund"), its offering document or prospectus contains important information on selling restrictions and risk factors, you should read them carefully before entering into any transaction. It is your responsibility to be aware of and to observe all applicable laws and regulations of any relevant jurisdiction. AXA IM Asia does not intend to offer any Fund in any country where such offering is prohibited.

The offer, distribution, sale or re-sale of fund units/shares in Taiwan requires approval from and/or registration with Taiwanese regulatory authorities. To the extent that any units/shares of the Funds are not so licensed or registered, such units/shares are made available in Taiwan on a private placement basis only to banks, bills houses, trust enterprises, financial holding companies and other qualified entities or institutions (collectively, "Qualified Institutions") and other entities and individuals meeting specific criteria ("Other Qualified Investors") pursuant to the private placement provisions of the Rules Governing Offshore Funds. No other offer or sale of such units/shares in Taiwan is permitted. Taiwanese purchasers of such units/shares may not sell or otherwise dispose of their holdings except by redemption, transfer to a Qualified Institution or Other Qualified Investor, transfer by operation of law or other means approved by the Taiwan Financial Supervisory Commission.

For Malaysian investors: as the recognition by the Malaysian Securities Commission pursuant to Section 212 of the Malaysian Capital Markets and Services Act 2007 has not been / will not be obtained nor will this document be lodged or registered with the Malaysian Securities Commission, the shares referred to hereunder (if any) are not being and will not be deemed to be issued, made available, offered for subscription or purchase in Malaysia and neither this document nor any other document or other material in connection therewith should be distributed, caused to be distributed or circulated in Malaysia.

For Thailand investors: nothing in this document shall constitute in any manner whatsoever a proposal to make available, offer for subscription or purchase or to issue an invitation to purchase or subscribe for any securities in Thailand or a proposal to implement any of the foregoing in Thailand nor has this document been approved by or registered with the Securities and Exchange Commission of Thailand ("SEC"). No person receiving a copy of this document may treat the same as constituting an invitation or offer to him in Thailand and such person shall not distribute or make available this document in Thailand. The issuer of this document shall not be liable in any manner whatsoever in the event this document is distributed or made available to any person in Thailand receiving a copy of this document. Since no application for approval has been or will be made to the SEC for the offering of the securities, or for the registration of this document, the securities shall not be offered for subscription or purchased or made available, whether directly or indirectly, in Thailand. It is the sole responsibility of recipients wishing to take any action upon this document to satisfy themselves as to the full observance of the laws of Thailand, to comply with all relevant government and regulatory approvals, and to comply with all applicable laws, including but not limited to exchange control laws.

For Investors in People's Republic of China (PRC): this document does not constitute a public offer of the product, whether by sale or subscription in the PRC. The product is not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the product or any beneficial interest herein without obtaining all prior PRC's governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions.

For Brunei investors: This document has not been delivered to, licensed or permitted by Autoriti Monetari Brunei Darussalam. Nor has it been registered with the Registrar of Companies. This document is for informational purposes only and does not constitute an invitation or offer to the public. As such, it must not be distributed or redistributed to and may not be relied upon or used by any person in Brunei other than the person to whom it is directly communicated and who belongs to a class of persons as defined under Section 20 of the Brunei Securities Market Order, 2013.

For Filipino investors: The shares or units referred to in this document (if any) have not been registered with the Securities and Exchange Commission under the Securities Regulation Code. Any future offer or sale thereof is subject to registration requirements under the Code unless such offer or sale qualifies as an exempt transaction.



For Vietnam investors: This document does not contemplate an offer to sell the interests in any funds in Vietnam. The document has not been approved by the State Securities Commission of Vietnam or any other competent authorities in Vietnam which takes no responsibility for its contents. No offer to purchase the interests in any funds will be made in Vietnam and this document is intended to be read by the addressee only and must not be passed to, issued to, or shown to the public generally. The value of the interests in any funds, the possibility of gaining profit and the level of risk stipulated in this document is purely for reference purposes only and may change at any time depending on market status. Investment in fund(s) does not carry any assurance that investors will make a profit. Investors should themselves carefully balance the risks and the level of those risks before they make any decision to invest in any funds. It is investors' responsibilities to ensure that they are eligible to make investment in any funds. Investors are responsible for obtaining all applicable approvals and complying with requirements under Vietnamese laws.

MSCI: Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.